Unknown

Dataset Information

0

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.


ABSTRACT: Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib. Despite three approved therapeutic options, the cross-resistant BCR-ABL(T315I) mutation and compound mutants selected on sequential inhibitor therapy remain major clinical challenges. We report design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants. AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABL(T315I)-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens. Our work supports clinical evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.

SUBMITTER: O'Hare T 

PROVIDER: S-EPMC2804470 | BioStudies | 2009-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4359310 | BioStudies
1000-01-01 | S-EPMC5099696 | BioStudies
2010-01-01 | S-EPMC3066561 | BioStudies
1000-01-01 | S-EPMC5833368 | BioStudies
2016-01-01 | S-EPMC4916441 | BioStudies
1000-01-01 | S-EPMC2893099 | BioStudies
2012-01-01 | S-EPMC3681494 | BioStudies
2018-01-01 | S-EPMC6312196 | BioStudies
1000-01-01 | S-EPMC5352360 | BioStudies
2010-01-01 | S-EPMC4134510 | BioStudies